Journal article
A nipple shield delivery system for oral drug delivery to breastfeeding infants: Microbicide delivery to inactivate HIV
International journal of pharmaceutics, v 434(01-Feb), pp 224-234
15 Sep 2012
PMID: 22634141
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Cross sectional diagram of milk leaving breast passing through nipple shield delivery system insert.
A new drug delivery method for infants is presented which incorporates an active pharmaceutical ingredient (API)-loaded insert into a nipple shield delivery system (NSDS). The API is released directly into milk during breastfeeding. This study investigates the feasibility of using the NSDS to deliver the microbicide sodium dodecyl sulfate (SDS), with the goal of preventing mother-to-child transmission (MTCT) of HIV during breastfeeding in low-resource settings, when there is no safer alternative for the infant but to breastfeed. SDS has been previously shown to effectively inactivate HIV in human milk. An apparatus was developed to simulate milk flow through and drug release from a NSDS. Using this apparatus milk was pulsed through a prototype device containing a non-woven fiber insert impregnated with SDS and the microbicide was rapidly released. The total SDS release from inserts ranged from 70 to 100% of the average 0.07g load within 50ml (the volume of a typical breastfeed). Human milk spiked with H9/HIVIIIB cells was also passed through the same set-up. Greater than 99% reduction of cell-associated HIV infectivity was achieved in the first 10ml of milk. This proof of concept study demonstrates efficient drug delivery to breastfeeding infants is achievable using the NSDS.
Metrics
Details
- Title
- A nipple shield delivery system for oral drug delivery to breastfeeding infants: Microbicide delivery to inactivate HIV
- Creators
- Stephen E Gerrard - BioScience Engineering Research Group, Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge, United KingdomMary Lynn Baniecki - FHI 360, Durham, NC, USADavid C Sokal - FHI 360, Durham, NC, USAMary K Morris - Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USASandra Urdaneta-Hartmann - Department of Microbiology and Immunology, and Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USAFred C Krebs - Department of Microbiology and Immunology, and Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USABrian Wigdahl - Department of Microbiology and Immunology, and Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USABarbara F Abrams - Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USACarl V Hanson - Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USANigel K.H Slater - BioScience Engineering Research Group, Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge, United KingdomAlexander D Edwards - Reading School of Pharmacy, University of Reading, Whiteknights, Reading, United Kingdom
- Publication Details
- International journal of pharmaceutics, v 434(01-Feb), pp 224-234
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000306479400028
- Scopus ID
- 2-s2.0-84864133985
- Other Identifier
- 991014878025204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Pharmacology & Pharmacy